Several driver gene mutations such as EGFR, ALK, and ROS1 have been found, resulting in a dramatic change in the treatment landscape of non-squamous NSCLC: from empirical cytotoxic drugs to targeted therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.